Bridging Sunitinib Exposure to Time‐to‐Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker

Hepatocellular carcinoma (HCC) is third in cancer‐related causes of death worldwide and its treatment is a significant unmet medical need. Sunitinib is a selective tyrosine kinase inhibitor of the angiogenic biomarker: soluble vascular endothelial growth factor receptor‐2 (sVEGFR(2)). Sunitinib fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Ait‐Oudhia, S, Mager, DE, Pokuri, V, Tomaszewski, G, Groman, A, Zagst, P, Fetterly, G, Iyer, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131886/
https://www.ncbi.nlm.nih.gov/pubmed/27300260
http://dx.doi.org/10.1002/psp4.12084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131886/
https://www.ncbi.nlm.nih.gov/pubmed/27300260
http://dx.doi.org/10.1002/psp4.12084

Ejemplares similares